Back to MW MARSHALL WACE, LLP

RXRXRXRX
Showing 6 of 12 quarters

Position history for MWMARSHALL WACE, LLP's holdings in RECURSION PHARMACEUTICALS IN

Yes. Marshall Wace holds 4,714,577 shares of RXRX (Recursion Pharmaceuticals in), worth $17.3M, as of its Q2 2026 13F filing. It increased the position by 1,837,649 shares (+63.9%) from Q1 2026. Marshall Wace has held RXRX since Q1 2025, across 6 quarterly 13F filings.

Current Value

$17.3M

Current Shares

4.7M

Total Value Change

+$15.5M

Total Shares Change

+4.4M

Quarter-by-Quarter History
QuarterActionSharesChangeValueWeightPriceConviction
2026-Q2
Latest
Increased
4.7M
+63.9%
$17.3M0.0%$3.67
41
2026-Q1
Increased
2.9M
+1169.6%
$8.8M0.0%$3.54
44
2025-Q4
Increased
226,609
+189.6%
$926,8300.0%$4.11
40
2025-Q3
Decreased
78,259
-9.3%
$381,9030.0%$4.91
0
2025-Q2
Decreased
86,312
-74.1%
$436,7390.0%$5.03
0
2025-Q1
New
333,612
-
$1.8M0.0%$5.81
36

Other major holders of RXRX: BAILLIE GIFFORD & CO, ARK Investment Management LLC

Analytics tracking helps us improve the product. Essential functions stay on either way. How analytics data is used